LONDON (Alliance News) - Personalised medicine and biotechnology company Epistem Holdings PLC on Thursday said its Genedrive point-of-care hepatitis C test has successfully completed its first external assessment.
The assessment was carried out on reference material and patient samples at the Institut Pasteur in Paris.
The success of the first test will allow clinical trials of the test to start, with Epistem anticipating regulatory approval and a market launch of the product in 2017.
"The commencement of clinical trials of our HCV assay is an important step in our ongoing commercialisation of Genedrive, alongside the introduction of our TB test into the Indian market," said Ian Gilham, Epistem's chairman.
"The excellent results seen with HCV serve as a key proof of principle of our ability to develop blood-based tests and allow us to proceed with the development of tests for Hepatitis B and HIV, positioning Genedrive as the point of care platform of choice for the diagnosis of infectious diseases," he added.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
